Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial

Transfusion

Volumn 58, Issue 5, 2018, Pages 1210-1217

  Norris, Philip J ^a,b   Kaidarova, Zhanna ^a   Maiorana, Erica ^c   Milani, Silvano ^d   Lebedeva, Mila ^a   Busch, Michael P ^a,b   Custer, Brian ^a,b   Rebulla, Paolo ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Italian National Data Center   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1;

BLOOD; CONTROLLED STUDY; DISINFECTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION;

BLOOD PLATELETS; DISINFECTION; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNIZATION; ISOANTIBODIES; PLATELET TRANSFUSION; ULTRAVIOLET RAYS;

EID: 85048092298     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/TRF.14534     Document Type: Article

References (29)

1. Howard JE, Perkins HA. The natural history of alloimmuni-zation to platelets. Transfusion 1978;18:496-503.
2. Dutcher JP, Schiffer CA, Aisner J, et al. Long-term follow-up patients with leukemia receiving platelet transfusions: iden-tification of a large group of patients who do not become alloimmunized. Blood 1981;58:1007-11.
3. Doughty HA, Murphy MF, Metcalfe P, et al. Relative impor-tance of immune and non-immune causes of platelet refrac-toriness. Vox Sang 1994;66:200-5.
4. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
5. Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981;58:122-8.
6. Fauchet R, Genetet B, Gueguen M, et al. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion 1982;22:320-2.
7. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmu-nization in patients with leukemia. Blood 1983;62:815-20.
8. Fisher M, Chapman JR, Ting A, et al. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 1985;49:331-5.
9. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72: 964-9.
10. Sniecinski I, O’Donnell MR, Nowicki B, et al. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402-7.
11. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-8.
12. Levin MD, Kappers-Klunne M, Sintnicolaas K, et al. The value of alloantibody detection in predicting response to HLA-matched platelet transfusions. Br J Haematol 2004;124: 244-50.
13. Kao KJ. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study. Blood 1992;80:2931-7.
14. Slichter SJ, Deeg HJ, Kennedy MS. Prevention of platelet alloimmunization in dogs with systemic cyclospor-ine and by UV-irradiation or cyclosporine-loading of donor platelets. Blood 1987;69:414-8.
15. Kao KJ, Huang ES, Donahue S. Characterization of immu-nologic tolerance induced by transfusion of UV-B– irradiated allogeneic mononuclear leukocytes. Blood 2001; 98:1239-45.
16. Fast LD, DiLeone G, Edson CM, et al. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002;42:1318-25.
17. Fast LD, Dileone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006;46:642-8.
18. Jackman RP, Heitman JW, Marschner S, et al. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumina-tion and riboflavin treatment. Transfusion 2009;49:2686-99.
19. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007;84:1174-82.
20. Jackman RP, Muench MO, Heitman JW, et al. Immune mod-ulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013; 53:2697-709.
21. Grana NH, Kao KJ. Use of 8-methoxypsoralen and ultraviolet-A pretreated platelet concentrates to prevent alloimmunization against class I major histocompatibility antigens. Blood 1991;77:2530-7.
22. Truitt RL, Johnson BD, Hanke C, et al. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allo-geneic bone marrow transplantation. J Immunol 1999;163: 5145-56.
23. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
24. Rebulla P, Vaglio S, Beccaria F, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion 2017;57:1171-83.
25. Carrick DM, Norris PJ, Endres RO, et al. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion 2011;51:2092-101.
26. Jackman RP, Deng X, Bolgiano D, et al. Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion 2014;54: 672-80.
27. Jackman RP, Deng X, Bolgiano D, et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013;121:3261-6.
28. Kao KJ, Cook DJ, Scornik JC. Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody. Blood 1986;68:627-32.
29. Boshkov LK, Kelton JG, Halloran PF. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura. Br J Haematol 1992;81:552-7.